<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468100</url>
  </required_header>
  <id_info>
    <org_study_id>DRN-CFR-III</org_study_id>
    <secondary_id>348 eff date 23.06.2017</secondary_id>
    <nct_id>NCT04468100</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis</brief_title>
  <official_title>A Multicenter Prospective Randomized Comparative Study of Pharmacokinetics, Clinical Efficacy and Safety of Tigerase® (JSC GENERIUM, Russia) vs. Pulmozyme® (Hoffmann-La Roche, Switzerland) as Part of Complex Therapy in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AO GENERIUM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AO GENERIUM</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety&#xD;
      of Tigerase® compared Pulmozyme® in patients with Cystic Fibrosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) is a common hereditary disease with an autosomal recessive type of&#xD;
      inheritance, characterized by systemic damage to the exocrine glands, mainly the&#xD;
      bronchopulmonary and gastrointestinal systems. CF is usually characterized by a severe course&#xD;
      and poor prognosis. The severity of the disease and the life expectancy of the patient with&#xD;
      CF is determined primarily by the state of the bronchopulmonary system; more than 90% of&#xD;
      patients die from lung diseases.&#xD;
&#xD;
      CF Pulmonary damage develops as a result of a gene mutation - cystic fibrosis transmembrane&#xD;
      regulator of ion conductivity Na and Cl (CFTR-cystic fibrosis transmembrane regulator). The&#xD;
      main function of CFTR is to regulate the transport of sodium and chlorine across the cell&#xD;
      membrane and is part of the cAMP-dependent chlorine channel. CFTR-protein dysfunction in the&#xD;
      bronchial tree epithelial cells leads to a blockage of the chlorine ions transport and an&#xD;
      increase in the sodium ions absorption, and impaired fluid secretion through the epithelial&#xD;
      cells apical membrane.&#xD;
&#xD;
      Dornase alpha, a human recombinant deoxyribonuclease 1 (rhDNase, rhDNase) hydrolyzes&#xD;
      extracellular DNA (viscous polyanion) that enters the sputum from destroyed neutrophils,&#xD;
      thereby reducing the adhesion and viscosity of sputum. In CF patients dornase alpha is used&#xD;
      as symptomatic therapy in combination with standard therapy in patients with a forced vital&#xD;
      capacity (FVC) index of at least 40% of the proper value.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2017</start_date>
  <completion_date type="Actual">May 16, 2018</completion_date>
  <primary_completion_date type="Actual">May 16, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in forced expiratory volume in the first second of a forced expiratory maneuver (FEV1) compared to baseline</measure>
    <time_frame>FEV1 - forced expiratory volume in the first second of a forced expiratory maneuver by standard spirometry</time_frame>
    <description>Week 24 ± 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in forced lung capacity (FVC) compared to baseline</measure>
    <time_frame>Week 24 ± 1</time_frame>
    <description>FVC - forced lung capacity by standard spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of exacerbations of chronic pulmonary disease</measure>
    <time_frame>Week 24 ± 1</time_frame>
    <description>Clinical symptoms of chronic pulmonary disease exacerbation required antibiotic therapy in CF patients, include the presence of at least 4 of 12 possible signs or symptoms&#xD;
A change in color or amount of sputum;&#xD;
The appearance or intensification of hemoptysis;&#xD;
Strengthening cough;&#xD;
Increased shortness of breath;&#xD;
Increased malaise, fatigue or lethargy;&#xD;
Temperature above 38 ° C;&#xD;
Anorexia or weight loss;&#xD;
Sinuses pain or soreness;&#xD;
Changes in the nature of sinuses mucus;&#xD;
Changes in chest physical examination;&#xD;
Pulmonary function decrease at list 10% or more;&#xD;
Radiographic changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days before the chronic pulmonary disease exacerbation development</measure>
    <time_frame>Week 24 ± 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight compared to baseline</measure>
    <time_frame>Week 24 ± 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average score for the &quot;Symptoms&quot;, &quot;Activity&quot;, &quot;Influence&quot; subscales, as well as the average total score of the St. George's Respiratory Questionnaire (SGRQ), version 2.2</measure>
    <time_frame>Week 24 ± 1</time_frame>
    <description>St. George's Respiratory Questionnaire (SGRQ), a questionnaire for patients with respiratory diseases is designed to assess the chronic obstructive pulmonary disease patients quality of life.&#xD;
The questionnaire consists of 76 questions, which are grouped in 3 parts:&#xD;
The first part - symptoms - measures the degree of anxiety caused by respiratory symptoms.&#xD;
The second part - activity - measures the limitation of mobility and physical activity.&#xD;
The third part - the influence - evaluates the existing psychosocial consequences of bronchial obstruction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Tigerase®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dornase alfa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmozyme®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dornase alfa</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tigerase®</intervention_name>
    <description>2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days</description>
    <arm_group_label>Tigerase®</arm_group_label>
    <other_name>dornase alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pulmozyme®</intervention_name>
    <description>2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days</description>
    <arm_group_label>Pulmozyme®</arm_group_label>
    <other_name>dornase alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Patient Informed Consent Form for participation in the study;&#xD;
&#xD;
          2. Men and women 18 years and older;&#xD;
&#xD;
          3. Diagnosis of cystic fibrosis, defined as the presence of disease symptoms and a&#xD;
             positive sweat test and / or detection of 2 mutations of the MVTR gene during&#xD;
             genotyping;&#xD;
&#xD;
          4. FEV1 ≥40% and ≤100% of the proper value;&#xD;
&#xD;
          5. The ability to understand the protocol requirements, to give written consent to&#xD;
             participate in the study (including the use and transfer of information about the&#xD;
             patient's health status related to the study).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to any of used study drug, to their components, as well as a history&#xD;
             of significant allergic reactions;&#xD;
&#xD;
          2. Acute respiratory infection or exacerbation of chronic pulmonary disease within 4&#xD;
             weeks prior to screening and without corticosteroid or antibiotic therapy;&#xD;
&#xD;
          3. Concomitant diseases and conditions with potential impact the patients safety,&#xD;
             including:&#xD;
&#xD;
               -  Severe renal impairment (serum creatinine more than 1.5 times higher than the&#xD;
                  upper limit of normal);&#xD;
&#xD;
               -  Severe liver impairment (alanine aminotransferase (ALT) or aspartate&#xD;
                  aminotransferase (AST) blood serum activity is 2.5 times or more higher than the&#xD;
                  upper limit of the laboratory norm);&#xD;
&#xD;
          4. A history of lung transplantation or planned transplantation during this study;&#xD;
&#xD;
          5. The presence of antibodies to HIV, active viral hepatitis B and / or C and / or&#xD;
             cirrhosis in the history or detected on Screening;&#xD;
&#xD;
          6. Pregnancy and lactation;&#xD;
&#xD;
          7. Refusal of patients with preserved reproductive potential to use adequate&#xD;
             contraception throughout the study and within 30 days after the end of the study;&#xD;
&#xD;
          8. Patients who underwent a blood or blood components transfusion within 10 days prior to&#xD;
             screening;&#xD;
&#xD;
          9. Drug or alcohol abuse at the time of Screening or in the past;&#xD;
&#xD;
         10. Patient's participation in any other clinical trials and / or administration of an&#xD;
             experimental drug within 30 days prior to the Screening Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oksana A. Markova, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AO GENERIUM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Barnaul</city>
        <state>Altai Region</state>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crimean federal university named after V.I.Vernadsky</name>
      <address>
        <city>Simferopol</city>
        <state>Crimea Republic</state>
        <zip>295007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical hospital named after G.G. Kuvatov</name>
      <address>
        <city>Ufa</city>
        <state>Republic Of Bashkortostan</state>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan state medical University of Ministry of health, Hospital Therapy Department</name>
      <address>
        <city>Kazan</city>
        <state>Republic Of Tatarstan</state>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional clinical hospital No. 1</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovsk Region</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital named after D.D. Pletnev</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Multidisciplinary Hospital No. 2</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional clinical Hospital</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific medical center of General Medicine and pharmacologies</name>
      <address>
        <city>Stavropol</city>
        <zip>355000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomsk national medical research Center of the Russian Academy of Sciences, Genetic Clinic Research Institute medical genetics</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd State Medical University, Department of clinical pharmacology and intensive care</name>
      <address>
        <city>Volgograd</city>
        <zip>400066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Clinical Hospital No. 1 &quot;, Cystic Fibrosis center</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical hospital No. 2</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://www.researchgate.net/publication/339557202_Efficacy_and_safety_of_the_biosimilar_medicinal_product_TigeraseR_dornase_alfa_in_long-term_symptomatic_treatment_of_patients_with_cystic_fibrosis_results_of_a_phase_III_clinical_trial</url>
    <description>Efficacy and safety of the biosimilar medicinal product Tigerase® (dornase alfa) in long-term symptomatic treatment of patients with cystic fibrosis: results of a phase III clinical trial</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dornase</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Pancreatic Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Tigerase®</keyword>
  <keyword>DNase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

